First American Trust Fsb buys $5.5 Million stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : First American Trust Fsb scooped up 47,958 additional shares in Johnson & Johnson during the most recent quarter end , according to a recent disclosure to the SEC on Apr 5, 2016. The investment management firm now holds a total of 50,427 shares of Johnson & Johnson which is valued at $5.5 Million.Johnson & Johnson makes up approximately 1.94% of First American Trust Fsb’s portfolio.

Other Hedge Funds, Including , Hollencrest Securities reduced its stake in JNJ by selling 76 shares or 0.59% in the most recent quarter. The Hedge Fund company now holds 12,838 shares of JNJ which is valued at $1.4 Million. Johnson & Johnson makes up approx 0.24% of Hollencrest Securities’s portfolio.Lvm Capital Management Ltdmi reduced its stake in JNJ by selling 1,585 shares or 1.35% in the most recent quarter. The Hedge Fund company now holds 115,464 shares of JNJ which is valued at $12.6 Million. Johnson & Johnson makes up approx 4.00% of Lvm Capital Management Ltdmi’s portfolio.Renaissance Investment Group reduced its stake in JNJ by selling 202 shares or 0.98% in the most recent quarter. The Hedge Fund company now holds 20,471 shares of JNJ which is valued at $2.2 Million. Johnson & Johnson makes up approx 1.12% of Renaissance Investment Group’s portfolio.Beacon Financial Group reduced its stake in JNJ by selling 2,985 shares or 3.0% in the most recent quarter. The Hedge Fund company now holds 96,648 shares of JNJ which is valued at $10.6 Million. Johnson & Johnson makes up approx 2.28% of Beacon Financial Group’s portfolio.Cacti Asset Management reduced its stake in JNJ by selling 2,405 shares or 0.92% in the most recent quarter. The Hedge Fund company now holds 259,955 shares of JNJ which is valued at $28.4 Million. Johnson & Johnson makes up approx 3.05% of Cacti Asset Management’s portfolio.

On the company’s financial health, Johnson & Johnson reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.42. The company had revenue of $17811.00 million for the quarter, compared to analysts expectations of $17856.07 million. The company’s revenue was down -2.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.

Johnson & Johnson closed down -0.13 points or -0.12% at $108.97 with 68,23,922 shares getting traded on Monday. Post opening the session at $109.15, the shares hit an intraday low of $108.65 and an intraday high of $109.62 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.